<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The EORTC <z:hpo ids='HP_0001909'>Leukemia</z:hpo> Group comprises more than 45 qualified haematology centres in Europe </plain></SENT>
<SENT sid="1" pm="."><plain>The group promotes cooperation with new centres from Central and Eastern Europe with the aim to improve the standard and quality to the level in Western Europe </plain></SENT>
<SENT sid="2" pm="."><plain>Subcommittees on cytogenetics, molecular biology, and immunology, shared by experts in the field, are active and have meetings on a twice-yearly basis </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of our group is to organise phase II and phase III trials for patients with <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid or lymphoid <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:mp ids='MP_0009440'>myeloma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In 2000, 330 patients have been included in nine trials of the group </plain></SENT>
<SENT sid="5" pm="."><plain>Presently, more than 2600 patients included in previous and current studies are alive and under continuous follow-up allowing studies on the long-term results to be planned </plain></SENT>
</text></document>